CALGARY, June 13 /CNW/ - SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company developing a broad pipeline of protein-based pharmaceuticals and non-pharmaceutical products, today announced an agreement to acquire technology assets and in-license intellectual property related to the manufacture of biopharmaceuticals in safflower from Syngenta Crop Protection AG. The assets and intellectual property will allow SemBioSys to further increase its efficiency in the development of transgenic safflower by shortening the time it takes to develop safflower plants producing the desired pharmaceutical protein.
